September 14, 2004Journal of Clinical Oncology
Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet?
Key result
The SYT-SSX fusion gene type showed no association with clinical outcome in a multi-institutional study of 165 patients with synovial sarcoma, contrasting with previous retrospective reports.
Why the study?
Does the type of SYT-SSX fusion gene predict survival outcomes in patients with synovial sarcoma?
Population
Patients with synovial sarcoma
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
This editorial emphasizes the challenges and potential confounders in using retrospective data to validate molecular prognostic markers like SYT-SSX fusion genes in synovial sarcoma.
Structured PICO
Does the type of SYT-SSX fusion gene predict survival outcomes in patients with synovial sarcoma?
P
Population
Patients with synovial sarcoma (editorial discussing multiple studies, including a French multi-institutional study of 165 patients)
I
Intervention
Molecular prognostication using SYT-SSX fusion gene typing
O
Outcome
Metastasis-free survival and overall survivalhard clinical
This editorial emphasizes the challenges and potential confounders in using retrospective data to validate molecular prognostic markers like SYT-SSX fusion genes in synovial sarcoma.
Limitations
- Retrospective design
- Missing data
- Selection biases
- Different therapeutic approaches
- Potential confounders such as comorbidities, access to medical care, and varying center expertise
- Retrospective design of discussed studies
- Potential confounders like comorbidities and access to medical care
Cite This Study
Oliveira et al. (2004) conducted an editorial in Synovial sarcoma (n=165). SYT-SSX fusion gene type was evaluated on Clinical outcome and survival. The SYT-SSX fusion gene type showed no association with clinical outcome in a multi-institutional study of 165 patients with synovial sarcoma, contrasting with previous retrospective reports.